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Abstract
Background: Etodolac (ETD) is a non-steroidal anti-inflamatory antirheumatic drug. A survey of
the literature reveals that there is no method available for the determination of ETD in pure form
and pharmaceutical formulations by oxidation-reduction reactions.
Results: We describe three simple, sensitive and reproducible spectrophotometric assays (A-C)
for the determination of etodolac in pure form and in pharmaceutical formulations. Methods A and
B are based on the oxidation of etodolac by Fe3+ in the presence of o-phenanthroline (o-phen) or
bipyridyl (bipy). The formation of the tris-complex on reaction with Fe3+-o-phen and/or Fe3+-bipy
mixtures in acetate buffer solution at optimum pH was demonstrated at 510 and 520 nm with o-
phen and bipy. Method C is based on the oxidation of etodolac by Fe3+ in acidic medium, and the
subsequent interaction of iron(II) with ferricyanide to form Prussian blue, with the product
exhibiting an absorption maximum at 726 nm. The concentration ranges are 0.5–8, 1.0–10 and 2–
18 µg mL-1 respectively for methods A, B and C. For more accurate analysis, Ringbom optimum
concentration ranges were calculated, in addition to molar absorptivity, Sandell sensitivity,
detection and quantification limits.
Conclusion: Our methods were successfully applied to the determination of etodolac in bulk and
pharmaceutical formulations without any interference from common excipients. The relative
standard deviations were ≤ 0.76 %, with recoveries of 99.87 % – 100.21 %.
Background
Etodolac (ETD), 1,8-diethyl-1,3,4,9-tetrahydropyrano-
[3,4-b]indole-1-acetic acid [1], is a non-steroidal anti-
inflamatory antirheumatic drug (Scheme 1). A survey of
the literature reveals that there are very few reported meth-
ods for the determination of ETD in biological fluids,
pharmaceutical formulations and in presence of its enan-
tiomer. Of those studies reported, the techniques used
include chromatography, HPLC [2-5], GC [6-8], in addi-
tion to spectrofluorimetric [9] and spectrophotometric
methods [9-11]. However, an extensive survey of the liter-
ature revealed that there is no method available for the
simultaneous determination of ETD in pure form and
pharmaceutical formulations by oxidation-reduction
reactions.
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Scheme 1: The chemical structure of Etodolac (ETD).
The aim of this study was to apply redox reactions in
developing simple, accurate, sensitive and reproducible
assays to analyse ETD in pure form and pharmaceutical
formulations, by employing iron(III) with o-phenanthro-
line (o-phen), bipyridyl (bipy) and ferricyanide. This
study describes spectrophotometric methods that can be
used in laboratories where modern and expensive equip-
ment, such as that required for GC or HPLC, is not avail-
able.
Results and discussion
Methods A and B
Absorption spectra
1, 10-Phenantholine and 2,2'-bipyridyl are organic bases
whose chemical structures are similar, and contain the
iron(II) specific group (18). Methods A and B are based
on the formation of tris(o-phenanthroline)-iron(II) or
tris(2,2'-bipyridyl)-iron(II) following the reaction of ETD
with Fe3+-o-phen or Fe3+-bipy respectively. The reaction
proceeds through the reduction of Fe3+ to Fe2+, with the
subsequent formation of an intense orange-red coloura-
tion attributable to the complex (12–20). The absorption
spectra of the coloured complexes under optimum condi-
tions were scanned in double beam mode against a rea-
gent blank over the range 400–900 nm, and recorded
according to general procedures. Characteristic λmax values
were obtained at 510 and 521 nm for methods A and B,
respectively (Figure 1). The experimental conditions were
established by varying each parameter individually (21)
and observing the effect on the absorbance of the col-
oured species. All the spectral characteristics, as well as
measured or calculated factors and parameters, are sum-
marised in Table 1.
Effect of pH
Of the buffers investigated, acetate solution proved to be
the optimal (universal, phosphate, thiel, borate and ace-
tate). A pH adjustment was necessary especially given the
acidic medium, because the reaction was affected by
change in pH over the range 2.5–5.6. The optimum pH
was 4.5 for both methods A and B; moreover, 4.0 mL of
buffer solution was sufficient for complete colour devel-
opment.
N
H
O
OH
O
Table 1: Quantitative parameters for methods A-C.
Parameter A B C
λmax, nm 510 521 726
Beer's conc. Range (µg mL-1) 0.5–8.0 1.0–10 2.0–18
Ringbom conc. Range (µg mL-1) 0.85–7.5 2.0–8.5 3.0–16.5
Detection limits (µg mL-1) 0.065 0.104 0.228
Quantification limit (µg mL-1) 0.217 0.347 0.76
Molar absorpitivity × 10 4(L mol-1 cm-1) 1.812 1.876 1.039
Sandell sensitivity (ng cm-2) 15.86 15.32 27.66
Regression equation a
Sy/x 0.202 0.285 0.246
Intercept 0.0078 - 0.0018 0.0011
Sa 0.142 0.201 0.2007
± tSa 0.365 0.517 0.516
Slope 0.0582 0.066 0.036
Sb 0.0285 0.0365 0.018
± tSb 0.0733 0.094 0.0462
Correlation coefficient (r) 0.9999 0.9999 0.9997
Mean ± SD% 99.87 ± 0.659 100.21 ± 0.727 99.875 ± 0.759
RSD% 0.66 0.73 0.76
Variance 0.434 0.528 0.576
SE 0.269 0.297 0.31
Student, s t-valueb (2.571) 1.16 0.323 1.07
Variance ratio F-test b (6.256) 1.06 1.29 1.406
a A = a + b c, where c is the concentration in µg mL-1.
b The theoretical t- and F-values, 2.571 and 6.256, respectively for five degree of freedom at 95% confidence level.Chemistry Central Journal 2008, 2:7 http://journal.chemistrycentral.com/content/2/1/7
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Effect of reagent concentration
The addition of 1.0 mL of Fe3+-o-phen (method A) or 1.5
mL of Fe3+-bipy (method B) solutions was sufficient to
obtain the maximum and reproducible absorbance for 6.0
µg mL-1 of ETD. Smaller amounts resulted in incomplete
complex formation. Increased concentration had no effect
on complex formation, although absorbance increased
slightly owing to the reagent background used.
Effects of temperature and heating time
The effects of temperature and heating time on the forma-
tion of the coloured complex were also studied. The reac-
tion of ETD with both reagents proceeded very slowly at
room temperature, with higher temperature employed to
accelerate the reaction. Maximum absorbance was
obtained following heating on a water bath at 80°C for
about 10 min with both Fe2+-phen and Fe2+-bipyridyl col-
oured complexes. Further heating caused no appreciable
change in the colour. The complex obtained was highly
stable for more than 12 h.
Method C
Absorption spectra
The formation of the Prussian blue (PB) complex was
employed in the qualitative detection of Fe (II). A deep
blue complex was formed from the reaction between
Fe(II) and hexacyanoferrate (III). As shown in Figure 1,
the chromogenic reagent blank (Fe(III) mixed with hexa-
cyanoferrate (III) in acidic medium) did not show strong
absorption in the visible region of the spectrum. However,
Absorption spectra of: (A) Fe(III)-1,10-phenanthroline with ETD (6.0 µg mL-1); (B) Fe(III)-2,2'-bipyridyl with ETD (6.0 µg mL-1)  and (C) Fe(III)- ferricyanide with ETD (6.0 µg mL-1) versus reagent blanks for each method Figure 1
Absorption spectra of: (A) Fe(III)-1,10-phenanthroline with ETD (6.0 µg mL-1); (B) Fe(III)-2,2'-bipyridyl with ETD (6.0 µg mL-1) 
and (C) Fe(III)- ferricyanide with ETD (6.0 µg mL-1) versus reagent blanks for each method.
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after addition of the acidic hydrolysis product of ETD, the
spectrum changed because of the formation of the PB
complex, which has a λmax of 726 nm.
The first step is the oxidation of Fe(II):
Fe2+ + [Fe(CN)6]3- → Fe3+ + [Fe(CN)6]4-
The second step is the formation of hexacyanoferrate (II)
complex (PB):
4Fe3+ + 3 [Fe(CN)6]4-+ acidic hydrolysis product of (ETD) 
→ Fe4 [Fe(CN)6]3
The complex formed is highly insoluble (Ksp = 3 × 10-41)
(22). Neither iron(III) nor ferricyanide solution absorb at
726 nm. Hence, the use of measured volumes of reagent,
and measurement against the corresponding reagent
blank gave a linear calibration for the drug. We herefore
report the formation and application of the Prussian blue
complex in the development of a sensitive spectrophoto-
metric method for the determination of ETD.
The optimum conditions were established by varying
parameters, such as iron(III), ferricyanide and acid con-
centrations, reaction time and the order in which the rea-
gents were added:
Optimum iron(III) and ferricyanide concentrations
Having studied the effect of iron(III) chloride concentra-
tion on colour development, it was observed that the
absorbance increased as the volume of 0.2% iron(III)
solution increased, reaching a maximum upon the addi-
tion of 2.0 mL of the 0.2% iron(III) solution to 6.0 µg mL-
1 of ETD and 2.0 mL of 0.2% ferricyanide solution in a
total volume of 10 mL. These results indicate that maxi-
mum absorbance was obtained when the final iron(III)
chloride concentration was 0.04%. Larger volumes of
iron(III) chloride (up to 4.0 mL) had no effect on the sen-
sitivity of the reaction. Similar observations were made
when varying volumes of 0.2% ferricyanide solution were
added to fixed amounts of ETD (6.0 µg mL-1) and iron(III)
chloride (2 mL; 0.2%), and diluted to 10 mL after full col-
our development. The results of this study reveal that the
concentrations of iron(III) and ferricyanide reagents are
not critical. However, 2.0 mL of 0.2% reagent solutions in
a total volume of 10 mL were used to ensure adequate rea-
gent concentrations for higher drug concentrations.
Effect of nature of acid, and its concentration
The reaction product, Prussian blue, was found to floccu-
late within 20–30 min of colour development. To delay
the flocculation, acid was added after full colour develop-
ment and before dilution. Sulphuric acid was found to
give more stable colour and reproducible results com-
pared to hydrochloric acid. A 1.0 mL volume of 10 M sul-
phuric acid in a total volume of 10 mL was found to be
adequate.
Effect of reaction time and stability of coloured species
The reaction is slow at 30 ± °2°C, but absorbance
increased with time and reached a maximum in 10 min,
with colouration remaining stable for at least 6 h.
Effect of order in which reagents were added
After fixing all other parameters, a few other experiments
were performed to ascertain the influence of the order in
which reagents were added. The following order: drug, fer-
ricyanide and iron(III), followed by sulphuric acid after
full colour development, gave maximum absorbance and
stability, and for this reason the same order of addition
was followed throughout the investigation.
Method validation
Linearity
Under the optimum conditions described, Beer's law
holds over the concentration ranges 0.5–8, 1–10 and 2–
18 µg mL-1 respectively for methods A, B and C. The opti-
mum concentration ranges of ETD that can be measured
accurately, as evaluated from the Ringbom plot, are 0.85–
7.5, 2.0–9.0 and 3.0–16.5 µg mL-1 using methods A, B and
C, respectively. We calculated the apparent molar absorp-
tivity, Sandell sensitivity, relative standard deviations for
six replicate determinations of 6.0 µg mL-1 and the regres-
sion equations (Table 1).
Sensitivity
The detection limit (LOD) for the proposed methods was
calculated using the following equation according to
IUPAC definition (23):
LOD = 3s/k;
where s is the standard deviation of replicate determina-
tion values under the same conditions as the sample anal-
ysis in the absence of the analyte, and k is the sensitivity,
namely the slope of the calibration graph. In accordance
with the formula, the detection limits obtained for the
absorbance were found to be 0.065, 0.104 and 0.228 µg
mL-1 for the ETD-Fe2+-phen, Fe2+-bipyridyl and Fe2+-ferri-
cyanide methods, respectively.
The limits of quantitation, LOQ, is defined as;
LOQ = 10 s/k
According to this equation, the LOQs were found to be
0.217, 0.347 and 0.76 µg mL-1 for the Fe2+-phen, Fe2+-
bipyridyl and Fe2+-ferricyanide methods, respectively.Chemistry Central Journal 2008, 2:7 http://journal.chemistrycentral.com/content/2/1/7
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Accuracy and precision
In order to determine the accuracy and precision of the
proposed methods, solutions containing four different
concentrations of ETD were prepared and analysed in six
replicates. The relative standard deviation as precision and
percentage relative error (Er %) as accuracy of the sug-
gested methods were calculated at 95% confidence levels,
and can be considered satisfactory. Precision was carried
out by six determinations at four different concentrations
in these spectrophotometric methods. The percentage rel-
ative error was calculated according the following equa-
tion:
Er % = [(found – added)/added] × 100
The inter- and intra-day precision and accuracy results are
shown in (Table 2). The analytical results for accuracy and
precision show that the methods proposed have good
repeatability and reproducibility.
Effects of interference
The interference criterion was an error of not more than ±
3.0 % in the absorbance. To test the efficiency and selec-
tivity of the proposed analytical methods (A-C) to phar-
maceutical formulations, we carried out a systematic
study of additives and excipients (e.g. lactose, glucose,
dextrose, talc, calcium hydrogen phosphate, magnesium
stearate and starch) that usually present in dosage forms.
Experiments showed that there was no interference from
additives or excipients for methods A-C (Table 3).
The main degradation products of etodolac are identified
as 7-ethyl-2(1-methylene propyl)-1H-indole-3-ethanol,
1,8 diethyl-1-methyl-1,3,4,9-tetrahydropyrano- [3,4-
b]indole and 7-ethyl tryptophol [24]. Consequently, there
was no interference of the degradation products in the
determination of the ETD in proposed methods.
Analytical applications
Because our three methods were successfully applied to
the determination of ETD in its pharmaceutical formula-
tions, they could therefore be used easily for the routine
analysis of pure ETD and its dosage forms. Moreover, to
check the methods' validity, dosage forms [Napilac cap-
sules (200 mg ETD per capsule) and Etodine capsules
(300 mg ETD per capsule)] were tested for possible inter-
ference with the standard addition method (Table 4). The
methods' performance was assessed using the t-test (for
accuracy) and a variance ratio F-value (for precision) com-
pared with the reference method [9] (for 95% confidence
level with five degrees of freedom (25)). The results
showed that the t- and F-values were less than the critical
value, indicating that there was no significant difference
between the proposed and reference method for ETD
(Table 5). Because the proposed methods were more
reproducible and had higher recoveries than the reference
method, they can be recommended for adoption in rou-
tine analysis in the majority of drug quality control labo-
ratories.
Table 2: The intra-day and inter-day precision and accuracy data for ETD obtained by the proposed methods (A – C).
Intra-day Inter-day
Method Added (µg mL-1)F o u n d  ±  S E  a, b (µg 
mL-1)
Precision RSD % Accuracy R.M.E % Founda, b (µg mL-
1)
Precision RSD % Accuracy R.M.E %
A 1 0.99 ± 0.45 1.11 -1.00 1.01 ± 0.20 1.49 1.00
3 3.02 ± 0.49 1.20 0.67 2.97 ± 0.37 0.91 -1.00
5 4.99 ± 0.26 0.64 -0.20 4.94 ± 0.31 0.77 -1.20
7 6.97 ± 0.24 0.59 -0.43 6.94 ± 0.34 0.85 -0.86
B 2 2.02 ± 0.55 1.34 1.00 2.01 ± 0.63 1.54 0.50
4 3.97 ± 0.31 0.76 -0.75 3.99 ± 0.46 1.13 -0.25
6 5.93 ± 0.29 0.71 -1.17 5.96 ± 0.43 1.06 -0.67
8 8.05 ± 0.36 0.88 0.625 7.97 ± 0.38 0.93 -0.38
C 4 3.98 ± 0.18 0.45 -0.50 4.01 ± 0.46 1.12 -0.50
8 7.95 ± 0.20 0.50 -0.625 8.03 ± 0.40 0.98 0.38
12 11.94 ± 0.33 0.82 -0.50 12.04 ± 0.48 1.16 0.33
16 16.02 ± 0.49 1.19 0.125 15.91 ± 0.54 1.32 -0.56
a Average of six determinations.
b Mean ± standard error.
RSD%, percentage relative standard deviation;
R.M.E %, percentage relative mean error.Chemistry Central Journal 2008, 2:7 http://journal.chemistrycentral.com/content/2/1/7
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Conclusion
The methods proposed are simpler, less time consuming
and more sensitive than those previously published. All
the proposed methods were more advantageous than
other reported visible spectrophotometric [9-11] methods
with respect to sensitivity, simplicity, reproducibility, pre-
cision, accuracy and stability of the coloured species for ≥
12 h. The proposed methods are suitable for the determi-
nation of ETD in pure form and pharmaceutical formula-
tions without interference from excipients such as starch
and glucose, suggesting potential applications in bulk
drug analysis.
Experimental
Apparatus
All absorption spectra were recorded using a Kontron 930
(UV-Visible) spectrophotometer (German) with a scan-
ning speed of 200 nm/min and a band width of 2.0 nm,
equipped with 10 mm matched quartz cells. A Hanna pH
meter (USA) was used for checking the pH of buffer solu-
tions.
Materials and reagents
All chemicals and materials were of analytical grade, and
all solutions were freshly prepared in bidistilled water.
Pure samples
Etodolac (ETD) pure grade was supplied by Pharco, Egypt.
The purity was found to be 100.35 ± 0.64 % according to
the Pharco method [26] in which the absorbance of
0.002% w/v etodolac solution in 0.1 N sodium hydroxide
was measured at 276 nm.
Standard Stock solutions
Stock solutions of ETD were prepared by dissolving 100
mg of pure drug in methanol, followed by dilution to 100
mL with the same solvent to obtain 1 mg mL-1standard
Table 3: Determination of ETD in presence of additives or excipients.
Material Amount (mg) Method A Method B Method C
Recovery a %± SD b Recovery a %± SD b Recovery a %± SD b
Lactose 50 99.63 ± 0.82 99.20 ± 0.78 100.2 ± 0.51
Glucose 50 98.84 ± 0.67 100.35 ± 1.22 99.55 ± 0.88
Dextrose 50 99.30 ± 0.78 98.70 ± 0.56 98.65 ± 0.46
Magnesium stearate 30 99.25 ± 0.75 99.55 ± 0.89 100.15 ± 1.30
Calcium hydrogen phosphate 50 99.50 ± 0.96 98.95 ± 0.73 99.40 ± 0.84
Talc 40 99.80 ± 0.61 100.40 ± 1.05 100.10 ± 0.95
Starch 50 100.05 ± 1.14 98.80 ± 0.69 99.75 ± 0.62
a 6.0 µg mL-1 of ETD was taken.
b Average of five determinations.
SD: Standard deviation.
Table 4: Determination of ETD in it's pharmaceutical dosage form applying the standard addition technique.
Dosage forms Taken (µg mL-1) Added (µg mL-1) Proposed methods Recovery a % ± RSD
Napilac capsules Etodine capsules
A 2.0 - 99.98 ± 0.19 100.01 ± 0.16
1.0 100.05 ± 0.20 99.99 ± 0.18
3.0 99.93 ± 0.32 99.60 ± 0.26
5.0 99.84 ± 0.47 100.35 ± 0.32
B 2.0 - 100.09 ± 0.21 99.95 ± 0.27
2.0 99.74 ± 0.26 99.60 ± 0.18
4.0 99.30 ± 0.38 100.10 ± 0.22
6.0 99.55 ± 0.55 99.70 ± 0.56
C 4.0 - 100.25 ± 0.19 100.08 ± 0.23
4.0 99.80 ± 0.34 100.40 ± 0.51
8.0 100.15 ± 0.45 98.90 ± 0.49
12 99.79 ± 0.62 100.05 ± 0.54
a Average of six determinations.Chemistry Central Journal 2008, 2:7 http://journal.chemistrycentral.com/content/2/1/7
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solutions. Working solutions were prepared by an appro-
priate dilution of the stock standard solution.
Market samples
Napilac capsules (200 mg ETD/Capsule) were provided
by Global Napi Co (Egypt) and Etodine capsules (300 mg
ETD/Capsule) were provided by Pharco (Egypt).
Reagents
1. Iron(III)-o-phenanthroline (27) was prepared by mix-
ing 0.198 g of 1,10 phenanthroline monohydrate (Fluka,
Swiss), 2 mL of 1 M HCl and 0.16 g of ferric ammonium
sulphate dodecahydrate (Aldrich, Germany) before dilu-
tion with bidistilled water to 100 mL in a calibrated flask.
2. Iron(III)-bipyridyl (27) was prepared by dissolving
0.16 g of 2, 2'-bipyridyl (Fluka, Switzerland) in 2 mL of 1
M HCl and 0.16 g of ferric ammonium sulphate dodec-
ahydrate, before dilution with bidistilled water to 100 mL
in a calibrated flask.
3. Anhydrous FeCl3 (Merck) and K3 [Fe(CN)6] (BDH Lab.
Chemicals, Poole, England) 0.2% (w/v) were prepared in
bidistilled water. Sulphuric acid (10 M) was prepared by
adding 555 mL of concentrated acid, (Sp. Gr. 1.83) to 445
mL of bidistilled water with cooling (28).
4. The acetate buffer solutions, with pH ranges from 2.56
– 5.6, were prepared by mixing appropriate quantities of
0.2 M sodium acetate with 0.2 M acetic acid to obtain the
desired pH as previously recommended (29).
Recommended analytical procedure
Methods A and B
100 µg mL-1 aliquots of the standard solutions (A: 0.05–
0.8 and B: 0.1–1.0 mL) were transferred to a series of 10
mL calibrated flasks. To these were added 1.0 mL of Fe3+-
o-phen (method A) or 1.5 mL of Fe3+-bipy (method B)
reagent solutions and 4.0 mL of acetate buffer (pH 4.5),
before heating on a water bath at 80°C for 10 min. The
mixture was cooled to room temperature (25 ± 1°C) and
the volume made up to the mark with bidistilled water.
The coloured complexes formed were measured at 510
and 521 nm against a reagent blank treated similarly
according to methods A and B.
Method C
Into a series of 10 mL calibrated flasks, aliquots (0.2–1.8
mL) of 100 µg mL-1 standard solutions were transferred
using a micro burette and the total volume adjusted to 3
mL by adding bidistilled water. Then, 2 mL each of FeCl3
(0.2 %) and K3Fe(CN)6 (0.2 %) were added to each flask,
mixed well and left to stand for 10 min. Finally, 1 mL of
10 M H2SO4 was added to each flask, diluted to the mark
with bidistilled water and mixed well. The absorbance of
the resulting solution was measured at 726 nm for ETD
against a reagent blank prepared similarly. A calibration
graph was constructed by plotting the absorbance against
the drug concentration or calculated regression equation.
Analysis of pharmaceutical formulations
Ten tablets were accurately weighed and powdered. An
accurately weighed quantity equivalent to 20 mg ETD was
dissolved in 20 mL of methanol and transferred to a 100
mL calibrated flask. The contents of the flask were shaken
for 10 min, and then made up to the mark with methanol.
The general procedure was then followed for concentra-
tion ranges already mentioned for methods A, B and C.
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